<DOC>
	<DOCNO>NCT00038909</DOCNO>
	<brief_summary>To identify causative mutation previously untreated patient hemophilia A enrol ReFacto® clinical safety efficacy study CTN 93-R833-0XX/C9741-28 , use two establish hemophilia mutation test laboratory ( one Europe one North America ) .</brief_summary>
	<brief_title>Study Evaluating ReFacto Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Patients enrol Study CTN 93R8330XX/C974128 , treat ReFacto® study eligible participation . The patient ( legal guardian ) must willing give write informed consent studyrelated procedure perform . A blood sample collect patient purpose study analyze one designated central laboratory . Any condition , investigator 's opinion , place patient undue risk .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>